
    practical issues that could not be resolved resulting in recruitment difficulties at sites.
  
['respiratory syncytial virus infections']
['pc786', 'placebo', 'soc']

        Inclusion Criteria:

          -  Received an allogeneic or autologous hematopoietic stem cell transplant (HSCT) using
             any conditioning regimen

          -  Experienced new onset of at least one of the following respiratory symptoms ≤5 days
             before study Day 1:

        Nasal congestion or stuffiness, runny nose (rhinorrhoea), cough, or sore throat OR
        Worsening of at least one of those symptoms, if symptoms are chronic OR Wheezing, sputum
        production, pleuritic chest pain, increased respiratory rate, signs on chest auscultation,
        hypoxia, increased supplemental oxygen requirement or new infiltrates on chest X-ray/CT

          -  A positive RSV diagnostic test

          -  Provided written informed consent

        Exclusion Criteria:

          -  Is intubated and requires invasive ventilation

          -  Has received any investigational RSV vaccine after HSCT, or has received any
             monoclonal anti-RSV antibodies within 4 months or 5 half-lives before participation

          -  Treatment with intravenous ribavirin

          -  Positive for test for influenza or parainfluenza

          -  Significant untreated bacteraemia or fungaemia

          -  Significant untreated bacterial, fungal, or viral pneumonia

          -  Precluded from participating as a result of treatment with another investigational
             drug or participation in another clinical trial

          -  Other disease or condition which would preclude the subject's participation in a
             clinical trial

          -  Is receiving an antiretroviral protease inhibitor

          -  Has chronic, active hepatitis infection

          -  Known alcohol or drug abuse
      